Sign In
Buy DXR
$10.50
-0.345 (-3.18%)
At Close: Jul 31, 2026
Data from Three New Studies and Two Ongoing Trials Presented at the Heart Failure Society of America Annual Scientific Meeting 2021 Data Highlight Importance of Blood Volume Analysis in Providing Appr
Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
08:30am, Tuesday, 07'th Sep 2021
Oak Ridge, TN, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Daxor Corpor a tion (NYSE:DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer M
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
08:30am, Wednesday, 01'st Sep 2021
Oak Ridge, TN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today it issued a corporate update in a Letter to S
Company forecasts further increase in sales driven by new distributor agreements
Data Led to Multi-Center Study In Progress At Three Leading Hospitals
Daxor Corporation to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021
08:30am, Friday, 28'th May 2021
NEW YORK, May 28, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that Michael Feldschuh, Daxor's President and Chief
NEW YORK, NY, May 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of
BREAKTHROUGH PATENT-PENDING TRACER DEVELOPED FOR BROAD USE
Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020
08:30am, Friday, 26'th Feb 2021
Revenues of Operating Division Increase by 50.4%
DAXOR CORPORATION RECEIVES ISO 13485 QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR THE BLOOD VOLUME ANALYZER (BVA-100®)
08:30am, Friday, 19'th Feb 2021
Important Milestone for International Distribution
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Cente
New Research Demonstrates the Clinical Utility with Daxor's Blood Volume Analyzer (BVA-100®) in Critical Care
08:30am, Thursday, 04'th Feb 2021
Study Presented At the Society for Critical Care Medicine (SCCM) 50th Congress
Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference
08:30am, Friday, 08'th Jan 2021
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative
Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
08:30am, Thursday, 10'th Dec 2020
NEW YORK, NY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume me
